Brief: Eloxx Pharmaceuticals Reports Fourth Quarter Results
31/03/2022 13:16
March 31 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS INC - AS OF DECEMBER 31, 2021, WE
HAD CASH
AND CASH EQUIVALENTS OF $42.3 MILLION
* ELOXX PHARMACEUTICALS- CASH AND CASH EQUIVALENTS COMBINED
WITH
$7.0 MILLION FROM CF FOUNDATION, EXPECT WILL BE SUFFICIENT TO
FUND OPERATIONS INTO Q2 2023
* ELOXX PHARMACEUTICALS INC - FOR THREE MONTHS ENDED
DECEMBER 31,
2021, INCURRED A NET LOSS OF $12.1 MILLION, OR $0.14 PER SHARE
Source text for Eikon: ID:nGNX4VJcJY
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome